华西口腔医学杂志

• 专栏论著 • 上一篇    下一篇

塞来昔布提高耐长春新碱细胞株KB/VCR细胞化疗敏感性的研究

闫怡轩  李伟忠   

  1. 南方医科大学南方医院口腔颌面外科,广州510515
  • 出版日期:2013-08-01 发布日期:2013-08-01
  • 通讯作者: 李伟忠,Tel:13570356680
  • 作者简介:闫怡轩(1985—),男,河北人,硕士,现工作于广东省妇幼保健院
  • 基金资助:

    广东省自然科学基金资助项目(10151051501000101,S2011010003841)

Celecoxib enhances the chemotherapy sensitivity of KB/VCR cell lines to vincristine

Yan Yixuan, Li Weizhong.   

  1. Dept. of Oral and Maxillofacial Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
  • Online:2013-08-01 Published:2013-08-01

摘要:

目的  研究选择性环氧化酶-2(COX-2)抑制剂塞来昔布影响口腔癌耐长春新碱细胞株KB/VCR细胞对长春新碱敏感性的效应,探讨其作用机制。方法  采用MTT法分别检测塞来昔布组、长春新碱组、塞来昔布+长春新碱组、塞来昔布+长春新碱+前列腺素E2 ( PGE2)组对KB/VCR细胞的生长抑制作用,用Western印迹法检测P-糖蛋白(Pgp)、Bcl-2和Bcl-XL的表达,流式细胞术检测塞来昔布对KB/VCR细胞凋亡的影响。采用SPSS 13.0软件进行统计分析。结果  塞来昔布+长春新碱组的细胞生长抑制率高于塞来昔布组、长春新碱组及塞来昔布+长春新碱+PGE2组(P<0.01)。塞来昔布+长春新碱组和塞来昔布组P-gp的表达显著低于长春新碱组及塞来昔布+长春新碱+PGE2组(P<0.01),塞来昔布+长春新碱组、塞来昔布+长春新碱+PGE2组和塞来昔布组Bcl-2、Bcl-XL的表达显著低于长春新碱组(P<0.01)。塞来昔布+长春新碱组、塞来昔布+长春新碱+PGE2组细胞凋亡率均显著高于长春新碱组、塞来昔布组,塞来昔布+长春新碱+PGE2组细胞凋亡率显著低于塞来昔布+长春新碱组(P<0.01)。结论  塞来昔布可以通过下调P-gp的表达及促进细胞凋亡,增强长春新碱耐药株KB/VCR细胞对长春新碱的敏感性。

关键词: KB/VCR细胞, 多药耐药, P-糖蛋白, 环氧化酶-2抑制剂, 细胞凋亡

Abstract:

Objective  To investigate the influence of celecoxib, cycloxygenase-2(COX-2) selective inhibitor, upon the proliferation of KB/VCR cells, and analyze the effect of celecoxib on the expression of P-glycoprotein(P-gp). Methods  MTT method was employed to study the inhibitory effect of celecoxib on KB/VCR cells, which were divided into vincristine(VCR) group, Celecoxib group, Celecoxib+VCR group, Celecoxib+VCR+prostaglandin E2 ( PGE2) group. Western blot was employed to detect the expression of P-gp, Bcl-2 and Bcl-XL. Flow cytometry was used to evaluate the apoptosis of KB/VCR cells. All of the data were statistically analyzed using SPSS 13.0 software package. Results  The growth inhibition rate of KB/VCR cells in Celecoxib+VCR group was significantly higher than that in Celecoxib group, VCR group and Celecoxib+VCR+PGE2 group(P<0.01). The expression of P-gp in Celecoxib+VCR group and Celecoxib group were markedly lower, compared with those in VCR group and Celecoxib+VCR+PGE2 group(P<0.01). The expression of Bcl-2, Bcl-XL in Celecoxib+VCR group,  Celecoxib+VCR+PGE2 group and Celecoxib group were significantly lower than those in VCR group(P<0.01). The apoptosis rate of Celecoxib+VCR group, Celecoxib+VCR+PGE2 group were significantly higher than those in VCR group and Celecoxib group(P<0.01). The apoptosis rate of Celecoxib+VCR+PGE2 group were significantly lower than those in Celecoxib+VCR group(P<0.01). Conclusion Celecoxib could enhance the toxicity of VCR against KB/VCR cells. The mechanism probably correlates with the downregulation of celecoxib on the expression of P-gp and the increase of apoptosis.

Key words:  KB/VCR cell, multidrug resistant, P-glycoprotein, cycloxygenase-2 inhibitor, apoptosis